HDAC Inhibition May Combat Resistance to Anti-PD-1 Therapy in Patients With Melanoma
ATLANTA – A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda) showed...
Search/Filter
Loading...
Next-generation TRK-targeted Therapeutic, LOXO-195, Shows Early Promise Against Tumors with Acquired Resistance to First-generation Therapeutics
ATLANTA – The investigational anticancer therapeutic LOXO-195 (now known as BAY 2731954), which targets a family of proteins called...
American Association for Cancer Research Inaugurates New Leadership at 2019 Annual Meeting
Dr. Elaine R. Mardis inaugurated as President ATLANTA – The American Association for Cancer Research (AACR) welcomes Elaine R....
Data From Two KEYNOTE Trials Show Pembrolizumab Benefited Patients With Advanced Small Cell Lung Cancer
ATLANTA – The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated,...
Umbralisib Shows Early Promise for Patients with Marginal Zone Lymphoma
ATLANTA – The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients...
Cancer Preventive Vaccine Showed Promising Results in Preclinical Model of Lynch Syndrome
“ATLANTA – Vaccination with as few as four tumor antigens generated antigen-specific responses, reduced intestinal tumors, and improved survival...
Gilteritinib Improved Survival for Patients With Acute Myeloid Leukemia
“ATLANTA – Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid...
Emil J Freireich Honored With AACR Award for Lifetime Achievement in Cancer Research
PHILADELPHIA – The American Association for Cancer Research (AACR) recognized Emil J Freireich, MD, FAACR, with the 2019 AACR...
Excess Body Weight Before age 50 is Associated With Higher Risk of Dying From Pancreatic Cancer
ATLANTA – Excess weight before age 50 may be more strongly associated with pancreatic cancer mortality risk than excess...
Mesothelin-targeted CAR T-cell Therapy Safe, Shows Early Promise in Patients With Advanced Solid Tumors
ATLANTA – A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major...